MedWatch

IO Biotech doses first patient in international cancer collaboration

Danish IO Biotech has initiated the first clinical trials with the company's main asset as first-line treatment of lung cancer. The study is conducted in collaboration with the immunoncologic drug Keytruda from US pharma giant MSD.

For the first time, Copenhagen-based biotech firm IO Biotech has dosed a patient with the company's immunoncologic candidate IO102 for treatment of metastatic non-small cell lung cancer (NSCLC).

In collaboration with the US drug group MSD, IO Biotech initiated a large phase I/II study testing IO Biotech's immune modulating vaccine in combination with the multi-blockbuster Keytruda (pembrolizumab).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier